Shandong Weigao Group Medical Polymer Company Limited (01066) completed a share repurchase on 13 February 2026, resulting in 0.16 million shares repurchased at a highest price of HKD 5.23 and a lowest price of HKD 5.15 per share. The aggregate price paid was HKD 0.83 million.

After this transaction, the number of shares excluding treasury shares decreased from 4,481.09 million to 4,480.93 million, while treasury shares increased from 41.24 million to 41.40 million. The total issued shares remained at 4,522.33 million. The repurchase represented approximately 0.0036% of the company’s previously issued shares (excluding treasury shares).

The company was granted a repurchase mandate on 27 May 2025 to repurchase up to 451.56 million shares. As of the latest update, 34.75 million shares have been repurchased under this mandate, accounting for 7.70% of the number of issued shares (excluding treasury shares) as of the mandate date. The moratorium period for any new share issuance or sale/transfer of treasury shares under this repurchase extends until 16 March 2026.